ArticleTechnology in cancer research & treatment
A New Risk Index Combining d-Dimer, Fibrinogen, HE4, and CA199 Differentiates Suspecting Endometrial Cancer From Patients With Abnormal Vaginal Bleeding or Discharge.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis.Computational and mathematical methods in medicine · 2022Pooled it
- Integrated Signature of Multiple Indices for Preoperative Predictive Stratification of Endometrial Hyperplasia Subtypes: A Retrospective Cohort Study.International journal of women's health · 2026Article
- Early Identification of Endometrial Malignancy in Postmenopausal Women with Asymptomatic Endometrial Thickening: A Novel Explainable Machine Learning Model.International journal of medical sciences · 2026Article
- Development and Validation of Differential Diagnosis Models and Nomograms Based on Serum D-Dimer and Other Multimodal Information for Borderline and Benign Epithelial Ovarian Tumors: A Multicenter Study.Diagnostics (Basel, Switzerland) · 2025Article
- Diagnostic Value of ADC in Distinguishing Endometrial Cancer from Atypical Endometrial Hyperplasia and Within Molecular Subtypes.International journal of women's health · 2025Article
- Using heart rate variability to evaluate the association between the autonomic nervous system and coagulation function in patients with endometrial cancer.Oncology letters · 2024Article
- Function of homocysteine and HE4 in endometrial carcinoma: verified by prospective experiment.Translational cancer research · 2024Article
- The role of ncRNAs and exosomes in the development and progression of endometrial cancer.Frontiers in oncology · 2024Review
- Article
- Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions.Diagnostics (Basel, Switzerland) · 2023Article
- Borderline Brenner tumor with abnormally high serum level of carbohydrate antigen 199: a rare case report and literature review.Irish journal of medical science · 2023Review
- Serum protein N-glycome patterns reveal alterations associated with endometrial cancer and its phenotypes of differentiation.Frontiers in endocrinology · 2023Article
- Article
- HE4 Tissue Expression as A Putative Prognostic Marker in Low-Risk/Low-Grade Endometrioid Endometrial Cancer: A Review.Current oncology (Toronto, Ont.) · 2022Review
- Review
- HE4 as a Biomarker for Endometrial Cancer.Cancers · 2021Review
- Combination IETA Ultrasonographic Characteristics Simple Scoring Method With Tumor Biomarkers Effectively Improves the Differentiation Ability of Benign and Malignant Lesions in Endometrium and Uterine Cavity.Frontiers in oncology · 2021Article
- Integrated Analysis of Microbiome and Transcriptome Data Reveals the Interplay Between Commensal Bacteria and Fibrin Degradation in Endometrial Cancer.Frontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo establish an efficient new risk index for screening patients with endometrial cancer from patients with abnormal vaginal bleeding or discharge.
methodA total of 254 patients with abnormal vaginal bleeding or discharge were included in this study. Several candidate markers, including HE4, CA125, CA199, CA153, AFP, CEA, d-dimer, and fibrinogen, were employed. A new risk index for endometrial cancer screening was established by binary logistic regression. The diagnostic value of the candidate markers and the new risk index were assessed by a receiver operating characteristic curve, sensitivity, and specificity.
resultsThe most valuable diagnostic indicator for endometrial cancer was HE4, followed by d-dimer and then fibrinogen (area under the receiver operating characteristic curve: HE4 = 0.794, d-dimer = 0.717, fibrinogen = 0.690). The new risk index was superior to a single application of markers and a widely used combination (HE4 and CA125). At the ideal cutoff level, the sensitivity and specificity were 91.34% and 70.08%, respectively. In addition, only patients without organic disease served as controls, which further increase its performance (area under the receiver operating characteristic curve = 0.932, sensitivity = 94.49%, and specificity = 77.42%).
conclusionsThe new risk index combining HE4, d-dimer, fibrinogen, and CA199 was the ideal combination for the screening of endometrial cancer. As a simple, rapid, nondestructive detection method, the new risk index is worth promotion in clinical practice, especially in primary medical institutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.